Cogitat

Cogitat operates at the intersection of non-invasive brain-computer interfaces, machine learning, and digital health. Its stated differentiator is device- and subject-agnostic EEG decoding: rather than depending on an implanted interface or a single headset, the company aims to translate brain activity into commands across compatible EEG hardware. This places it in an adjacent position to Neuralink, which is focused on implanted BCI systems, while Cogitat’s approach emphasizes non-invasive deployment and software decoding. The company’s product set covers upper-limb movement, motor imagery, mental commands, attention, meditation, and sleep, giving it a wider application surface than a single-condition medical device. Its 2025 AI in Healthcare accelerator participation and NATO DIANA cohort membership provide evidence of interest in healthcare and dual-use applications, but do not establish commercial scale or regulatory approval. The available peer-comparison records do not identify validated independent competitors, and Cogitat’s modest disclosed funding base of $601,345 indicates an early-stage position relative to better-capitalized neurotechnology companies.

Cogitat was founded in December 2020 and has developed from an early BCI research venture into a company with several defined EEG-decoding applications. Its disclosed funding history includes a pre-seed round in September 2021, a $601,345-equivalent Innovate UK grant announced on Mar 1, 2023, and an additional NATO DIANA grant recorded on Sep 4, 2025 with no public amount. The trajectory is therefore grant-led rather than driven by a large institutional equity financing. Product breadth has expanded across movement decoding, imagined movement, attention, meditation, and sleep, suggesting a reusable decoding platform rather than a single product. Visibility increased materially in 2024 through demonstrations covered by Sky News and a collaboration involving Imperial College London. The clearest commercial and clinical inflection point came in February 2025, when Cogitat entered the UK AI in Healthcare accelerator with a stroke-rehabilitation focus. Its NATO DIANA selection in the same month added a defence and dual-use validation pathway. Employee growth data is limited to an estimated 11–50 person band, so the pace of operational scaling cannot be confirmed.